To further validate the clinical significance of our findings, we next investigated the DNA methylation status at the −963 CpG site within the GABRP promoter, and GABRP expression in 15 paired clinical samples, which included primary ovarian carcinomas and adjacent normal tissues, from six patients diagnosed at early stage and nine patients at advanced stage. This evidence concerns the gene GABRP and ovarian carcinoma.